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Childhood membranoprotiferative glomerulonephritis type I: Limited
steroid therapy. Nineteen patients with biopsy proven membranopro-
liferative glomerulonephritis type I (MPGN 1) and a minimum of three
years of follow-up (mean 6.5 0,7 years) have been treated with an
uncontrolled regimen of limited corticosteroids. Initial therapy ranged
from 20 mg per os (po) every other day to 30 mg/kg/day i.v. for three
consecutive days, depending on clinical disease severity. Therapy was
then decreased based on each patient's improving clinical status. At
diagnosis creatinine clearance (Car) was < 80 mI/mm/I .73 m2 in 12
patients and < 50 in 2. All patients had hematuria and proteinuria, with
15 in the nephrotic range. Hypertension, present at diagnosis in 13,
developed in five others following institution of prednisone, and was
controlled medically. Renal biopsy was repeated after two years of
therapy prior to cessation of treatment (mean total treatment duration
38 3 months). Follow-up biopsy revealed decreased glomerular
inflammatory activity in 88% of patients. All patients have now been off
prednisone for 40 9 months. The mean Ce,. is 126 5mI/mm/i .73 m2.
Eight patients have normal urinalyses. These data suggest that early
therapy with a limited course of corticosteroids, and control of associ-
ated hypertension, may forestall progressive renal insufficiency in
children with MPGN type I.
Idiopathic membranoproliferative glomerulonephritis (MPGN)
is a primary glomerular disease that is a major cause of renal
insufficiency in children and young adults [1—4]. MPGN type I, the
most common variety, is characterized morphologically by sub-
endothelial deposits and an intact glomerular basement mem-
brane. The natural history of MPGN is variable, however, most
patients have a slowly progressive course such that, irrespective
of the type, 50% renal survival ranges from six to nine years [1—6].
The treatment of MPGN I remains controversial. Cytotoxic
agents [1, 2, 4, 7—10], antimalarials [4], platelet inhibitors [8, 11,
12], anticoagulants [7—9, 12], nonsteroidal antiinflammatory
agents [10, 11, 13], and corticosteroids [1, 14—16] have all been
prescribed, alone and in combination. However, analysis of
many reports, including several controlled clinical trials, has
been confounded by the addition of supplementary medications
on a random basis within a given patient population [1, 2, 4, 7,
12, 13], or the inclusion of assorted MPGN types within specific
treatment regimens [1—3, 12]. Corticosteroids have appeared to
produce some of the most encouraging results [1, 14, 15],
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although some clinical reports have suggested that unaccept-
able complications may obviate their use [4, 16]. Recently,
Donadio and Offord [17] questioned the value of any of the
published treatment regimens in affecting the course of MPGN.
Using life-table analysis, the authors concluded that none of the
available treatment options favorably affect long-term outcome
[17]. However, many of these therapeutic regimens were initi-
ated years after the onset of clinically apparent renal disease;
one factor which may affect such analytic scrutiny.
Based on the premise that significant inflammatory injury
may occur in the nascent stages of disease, and that corticoste-
roids may ameliorate the inflammatory process, we designed a
therapeutic regimen to provide early institution of prednisone.
To mitigate undesirable steroid-induced side effects we limited
the duration of therapy. The unique features of this regimen
include the initiation and gradual reduction of corticosteroid
dosage based on clinical parameters reflective of disease sever-
ity in conjunction with aggressive control of associated hyper-
tension. The present communication describes our experience
since instituting this approach in 1977 [14].
Methods
Patient population
Nineteen children with biopsy-proven MPGN I, and a mini-
mum of three years of follow-up, were treated by the Pediatric
Nephrology Service at the University of Colorado School of
Medicine and The Children's Hospital, Denver, between July
1977 and October 1991. All patients had idiopathic disease.
None had received prior immunosuppressive therapy.
Treatment regimen
An uncontrolled therapeutic regimen was designed to provide
individualized corticosteroid treatment based on pre-estab-
lished clinical criteria. Methylprednisolone was used for i.v.
therapy. Prednisone was administered orally. Following diag-
nostic renal biopsy, patients were placed in one of four treat-
ment categories based on the severity of their initial clinical
presentation (Table 1). Corticosteroid therapy was instituted at
30 mg/kg/day i.v. bolus (maximum 1 g) for three consecutive
days in those most severely affected (group IV), at 2 mg/kg/day
(maximum 60 mg) as a single oral dose for patients in group III,
or as alternate-day therapy for groups I and II. Corticosteroid
dosage when then decreased as each patient advanced through
the treatment categories based on individual improvement in
Ccr, urinary sediment and urinary protein excretion. However,
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Table 1. MPGN I treatment regimen: Disease seventy categorized by associated clinical findings
Group I Group II Group III Group IV
Ccr
mI/mm/i.73 m
Proteinuria
mg/m2/hr
Corticosteroid
therapy
>80
<40
20 mg qod
>80
>40
2 mg/kg/qoda
<80
>40
2 mg/kg/daya
<50
30 mg/kg/day
i.v. x 3 days,
then 2 mg/kg/daya
a Maximum 60 mg per dose
daily corticosteroids generally were not continued for more
than eight weeks. In most cases dosage reduction from category
II to category I followed a 6 to 12 week tapering schedule, after
a patient fulfilled the appropriate clinical criteria. The goal of
the regimen was for all patients eventually to receive pred-
nisone at no greater than 20 mg every other day, and to
complete at least two years of alternate day corticosteroid
therapy. Integral to the regimen, systemic hypertension was
aggressively controlled to maintain blood pressure within two
standard deviations of the mean for age. Once clinically stable
follow-up was every three to six months. The following clinical
and laboratory parameters were assessed: blood pressure,
height and weight, urinalysis, blood urea nitrogen, serum cre-
atinine, electrolytes, albumin, 24-hour urine for Cr and protein
excretion, C3 and C4, and/or CH5O complement levels. A renal
biopsy was repeated in 17 patients after two years of therapy in
anticipation of eventual cessation of corticosteroid treatment.
The clinical criteria for cessation of prednisone were: (1) a
normal CC,.; and (2) an absence of gross hematuria, nephrotic
range proteinuria, and active urinary sediment (such as, greater
than 20 to 30 RBC/hpf, and the presence of red cell casts). In
twelve patients who fulfilled these criteria, prednisone was
gradually reduced and discontinued shortly after the follow-up
biopsy revealed a complete resolution of glomerular inflamma-
tory activity. Five patients exhibiting biopsy evidence of per-
sistent glomerular inflammation were maintained on alternate-
day prednisone until a subsequent biopsy (1 patient), or a
significant improvement in the aforementioned clinical param-
eters (4 patients) suggested a resolution of active glomerular
injury. The decision to discontinue prednisone in two patients
was based on purely clinical grounds.
Histology
All biopsy specimens were examined using light, immunoflu-
orescent and electron microscopy (EM). A histologic scoring
system was designed to assess for active and chronic renal
injury. Active disease was determined by scoring for glomerular
cellularity, inflammatory activity, and capillary loop patency.
Chronic renal injury was evaluated by determining the extent of
glomerulosclerosis and interstitial area, largely reflective of
interstitial fibrosis. Morphologic scoring was performed in a
"blinded" fashion by a single pathologist (P.F.S.) on paraffin
embedded 2 to 3 micron thick sections from tissue fixed in
Bouin's solution or formalin. Sections were coded and read in
random order as follows:
Glomerular cellularity. Glomerular cellularity was estimated
from hematoxylin-eosin (H & E) stained sections by scoring
each glomerulus on a 0 to 3 + scale. The final cellularity score
was expressed as the percentage of the total possible score.
Inflammatory activity. Inflammatory activity also was deter-
mined from H & E stained sections by scoring as positive any
glomerulus with cellular crescents, overt necrosis, or greater
than four neutrophils. The total inflammatory activity was
expressed as the percentage of glomeruli with any of these
lesions.
Capillary loop patency. Capillary ioop patency was estimated
from periodic acid Schiff stained sections by scoring each
glomerulus on a 0 to 3 + scale: 0 indicated near total compro-
mise of capillary loop patency and 3+ indicated normal loops.
The final patency score was expressed as the percentage of the
total possible score.
Glornerulosclerosis. Glomerulosclerosis was assessed using
Masson trichrome stained sections, and was expressed as the
percent of glomeruli with fibrous crescents, segmental fibrosis
and adhesion to Bowman's capsule, tuft collapse and massive
thickening of Bowman's capsule, or global obsolescence. A
mean of 24 3 glomeruli was present on each biopsy specimen
for quantitation of glomerular cellularity, inflammatory activity,
capillary loop patency, and percent glomerulosclerosis.
Interstitial area. Interstitial area was measured as a percent-
age of the total tubulointerstitial area by a point count method
using Masson trichrome stained sections as follows: An 8-point
grid was in the ocular as the 40 x field was advanced through the
cortex by 1 mm intervals on a mechanical stage. The percent
interstitial area was determined by quantitating the percentage
of points overlying interstitium. If the grid passed over a
glomerulus or artery the field was adjusted for appropriate
localization over tubulointerstitial tissue. On each section 52
4points were counted for calculation of percent interstitial area.
Statistical analysis
Pre- and post-therapy biopsy scores were compared using the
Student's paired t-test (inflammatory activity, glomerulosclero-
sis and interstitial area), or the Wilcoxon signed-rank test
(glomerular cellularity and capillary loop patency). Biopsy
scores of patient cohorts at follow-up were compared using the
Student's unpaired t-test, or the Mann-Whitney U-test. Clinical
differences at follow-up were evaluated by chi-square analysis.
Statistical significance was considered at a P value of <0.05.
Data are expressed as mean standard error (sEM).
Results
Clinical data
Nineteen patients have been followed for 6.5 0.7 years
from the time of diagnosis (range 3.2 to 14.3 years). In all cases
except one the diagnosis was made and treatment was instituted
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Table 2. Clinical and laboratory features of selected patient cohorts
All pts
Initial treatment Inflammation on F/U biopsy
Alt day Daily Absent Present
"n" 19a 7a l2 12 a
Cr at DX
mI/mm/i .73 ,n
78 7 108 10 61 5 83 10 62 6
CcratF/U 126±5 125±7 127±7 135±5 107±6
ml/min/1.73 m2
Total Tx months 38 3 43 9 36 2 33 2 51 9
Total months off Tx 40 9 44 22 37 9 54 12 19 .5
F/U UA normal 42% 14% 58% 58% 20%
F/U microheme 32% 43% 25% 25% 40%
F/U proteinuria 21% 29% 17% 8% 40%
F/U micro + prot 5% 14% 0 8% 0
F/U low comp 37% 14% 50% 50% 20%
Abbreviations are: F/U microheme, microscopic hematuria with 4 to 10 RBCs/hpf at follow-up; F/U proteinuria, ito 2+ proteinuria at follow-up;
F/U micro + prot, coexistent microscopic hematuria and proteinuria at follow-up; F/U low comp, persistent low C3, C4, and/or CH5O at follow-up.
a
Includes patients in whom prednisone therapy was transiently resumed
within one year of clinically apparent disease (mean 5 1
months, range 2 to 18 months). Thus, the total duration of
clinically apparent renal disease was 6.9 0.8 years. At
diagnosis the mean age was 10.4 0.5 years (range 6.1 to 15.2
years).
The mean Ce,. at the time of diagnosis was 78 7 mllmin/l .73
m2 (Table 2). One patient (5%) began treatment in category I, 6
(32%) in category II, 10 (53%) in category III, and 2 (10%) in
category IV. Thus, 12 patients (63%) presented with Ce,. of less
than 80 mi/mm/i .73 m2, and were initially treated daily. The
total daily prednisone dosage in these twelve patients was 1.7
0.1 mg/kg/day. In most cases there was a rapid improvement in
Ce,. so that 10 patients were changed to alternate-day pred-
nisone (Category II; 0.8 0.05 mg/kg/day) after eight weeks of
daily therapy. Patients beginning therapy in groups II to IV had
a reduction in prednisone dosage to 20 mg every other day
(0.3 0.02 mg/kg/day) over 15 2 months (range 5 to 30
months). At the last follow-up the mean of all patients was
126 5 ml/minll.73 m2.
The mean initial duration of prednisone treatment of all
patients was 36 2 months (range 25 to 66 months). Cortico-
steroids have been completely discontinued in 17 patients for
42 10 months (range 5 to 131 months). Low dose alternate-
day prednisone was briefly resumed after therapy had been
discontinued for more than 12 months in two patients who
initially were treated for 29 and 66 months, respectively.
Non-nephrotic proteinuria associated with a CCr of <80 mllmin/
1.73 m2 recurred in the first, while the second developed a
recurrence of nephrotic-range proteinuria. Both patients now
have normal renal function and persistent mild proteinuria after
5.1 and 10.1 years of clinically apparent renal disease, respec-
tively. The total treatment duration of all patients was 38 3
months (Table 2).
Hypertension, defined as a systolic or diastolic blood pres-
sure greater than 2 standard deviations above normal for age,
was noted in 13 patients (68%) prior to therapy. Five additional
patients (26%) developed hypertension following institution of
prednisone. Only one patient did not receive antihypertensive
medication. Eight patients (42%) required three or more anti-
hypertensive medications (maximum of 5), and 17 (89%) re-
ceived an angiotensin converting enzyme inhibitor (ACE!) at
some point during their clinical course. All patients are now
normotensive, although eight (42%) remain on ACE! therapy.
Complications of corticosteroid therapy have been minimal.
Five patients developed asymptomatic hypertension that was
treated successfully. None developed lenticular cataracts.
Growth has been maintained with a mean height percentile prior
to therapy of 47 6% and at last follow-up 48 6%.
Histologic data
The diagnostic biopsies revealed findings characteristic of
MPGN I (Fig. 1A). There was marked endocapillary hypercel-
lularity, with thickening of peripheral capillary loops and
mesangial expansion resulting in reduced capillary loop pa-
tency. !n most cases neutrophil exudation was evident in some
glomeruli. Occasionally there were areas of necrosis or cellular
crescents, or both. Glomerulosclerosis and interstitial fibrosis
were evident in a few cases. Electron-dense subendothelial
deposits were documented by EM on the diagnostic biopsy
specimens in all patients.
Biopsy scores indicative of active glomerular disease are
shown in Figure 2. In most cases the follow-up biopsies
revealed a decrease in glomerular cellularity (P < 0.01) and
inflammatory activity (P < 0.01), and a marked increment in
capillary loop patency (P < 0.01). There appeared to be a
decrease in the typical deposits, with a mesangial proliferative
morphologic picture present on follow-up biopsy (Fig. IB). The
glomerulosclerosis scores increased from 5 2% at the time of
diagnosis to 23 5% following two years of therapy (P <0.01).
The percent interstitial area was unchanged from diagnosis
(26 4%) to follow-up (22 2%).
At the time of diagnosis patients fulfilling the clinical criteria
for daily therapy (groups III and IV; < 80 mI/mm/I .73 m2)
had glomerular morphology scores that were not statistically
different from those fulfilling the clinical criteria for alternate-
day medication. However, after two years of therapy patients
beginning in the severe clinical categories had significantly
greater glomerulosclerosis (30 6%) than those starting in
groups I and II (5 4%); these data are depicted in Figure 3
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Fig. 1. Representative photomicrographs of
renal biopsy findings at the time of diagnosis
(A), and following two years of prednisone
therapy (B).
(P < 0.05). In spite of these histologic differences, 58% of those
fulfilling the initial clinical criteria for daily therapy demon-
strated normal urinalyses at follow-up, in contrast to 14% of
those begun on alternate-day medication (Table 2). The C.of
these patient cohorts at follow-up was comparable, as was the
percentage of patients from both cohorts that developed hyper-
tension and were treated with ACEIs.
Glomerular inflammatory activity was improved in 15 pa-
tients, and completely resolved in 12 (Fig. 2) who were treated
with prednisone for 33 2 months. Five patients, including two
in whom prednisone therapy was transiently resumed, were
treated for a more extended period (51 9 months) for biopsy
evidence of persistent inflammatory activity (20 4%). These
five patients were noted to have a lower mean C1 at follow-up
than those in whom active inflammation was resolved (P <
0.02), but have still maintained normal renal function (Table 2).
Those with persistent glomerular inflammation also tended to
have more glomerulosclerosis at follow-up (36 11%) than
those with a resolution of inflammatory activity (18 5%, P>
0.05). Alternate-day therapy was discontinued in these patients
after a subsequent biopsy (1 patient) or a significant improve-
ment in clinical parameters (4 patients) suggested a resolution of
active glomerular injury.
Because of the relatively small number of patients there was
no statistical relationship between persistent hypocomplement-
emia at follow-up and the presence of hematuria, proteinuria, or
continued inflammatory activity on repeat renal biopsy. Nor
was there any statistical correlation between the findings on
urinalysis at follow-up and the presence of ongoing inflamma-
tory activity. However, in seven of eight patients with normal
urinalyses at follow-up, glomerular inflammation was com-
pletely resolved,
i.e
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Fig. 3. Glomerulosclerosis scores of seventeen patients at the tune of
diagnosis and following two years of therapy. Patients treated with
alternate-day therapy are depicted in the open circles; those initially
treated daily are shown in the closed circles.
Discussion
Although membranoproliferative glomerulonephritis was de-
scribed over 20 years ago by Gotoffet al [18] and West et al [19],
independently, optimal therapy remains controversial. Indeed,
Donadio and Offord [171, using life-table analysis in a review of
published treatment regimens, concluded that none of the
Capillary loop
patency
Fig. 2. Glomerular cellularity, inflammatory
activity and capillary loop patency scores of
seventeen patients at the time of diagnosis
and following two years of prednisone
therapy.
presently available treatment options favorably affect outcome.
It is noteworthy, however, that the duration of clinically
apparent renal disease prior to the initiation of therapy in the
clinical trails reviewed [171, was either not stated [16, 20],
unavailable [21], or greater than one [7] to three years [11—13].
Ten year survival by life-table analysis ranged from 60% to
85%. In the study of McEnery, McAdams and West [1],
patients were separated into those beginning prednisone within
one year of presentation and those beginning therapy after a
mean of 42 months. Those beginning prednisone within one
year fared much better, Of nine patients with MPGN I in the
less-than-one year group, none progressed to ESRD, in contrast
to three of nine who began therapy more than one year after
presentation [1]. West [22] has speculated that the major
inflammatory injury occurs in the nascent stages of disease, and
that subsequent damage may be due to alterations in glomerular
hemodynamics. Our experience employing a limited course of
corticosteroids combined with vigorous blood pressure control
is consistent with this view.
Other studies also have suggested that corticosteroids may
benefit children with MPGN I. Life-table analysis of the initial
International Study of Kidney Disease in Children (ISKDC)
experience [16], using a 50% decrement in glomerular filtration
rate as the sole end-point, found a five-year success rate of 57%
in the control group, compared to 95% in those treated with
alternate-day steroids. Although severe hypertension was
thought to nullify any salutary effect of therapy [16], a report
from the ISKDC in 1987 [23] again suggested a beneficial effect
of prednisone. Furthermore, while concerns have been ex-
pressed regarding an increase in hypertension with the usage of
corticosteroids in MPGN [4, 16], all patients in the present
report were successfully managed with antihypertensive medi-
cation. It is reasonable to conjecture that the control of hyper-
tension may have contributed to the observed outcome, as
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others have suggested that hypertension portends a worse
prognosis [1, 6]. Whether treatment with ACEIs is of special
significance, due to their glomerular hemodynamic effects, is
also speculative [241. An additional small controlled clinical
trial from Mexico has suggested that children with MPGN I
respond favorably to corticosteroids [15]. Four of 10 patients
treated with placebo developed ESRD over a mean of 6.5 years,
in contrast to none of eight treated with prednisone. Finally,
although there may be differences between the pediatric and
adult disease [2], it is interesting to note that a cohort of adult
patients in a report by Narita and Koyama [21] fared best when
treated with a combination of prednisone and cyclophospha-
mide.
The treatment of patients in the present report was not
controlled by prospective random design. However, all patients
except one began corticosteroid treatment within one year of
clinical presentation (mean 5 months) with the level of therapy
adjusted according to the patients' severity of illness. Twelve of
19 had an initial Cr of less than 80 mI/mini! .73 m2 and two, less
than 50. Fifteen patients were nephrotic and all but one were
hypertensive. At present the mean Crofall 19 patients is 126
5 mL/min/l .73 m2 following a limited course of prednisone,
averaging 38 3 months in length. Forty-two percent of
patients have normal urinalyses, and none are nephrotic after
6.9 0.8 years of clinically apparent renal disease.
At the time of diagnosis patients with the greatest reduction
in renal function (groups III and IV) had histologic scores that
were not statistically different from those with clinically milder
disease (groups land II). Conversely, after two years of therapy
those with greater clinical severity had more glomerulosclerosis
than those presenting with less severe disease (Fig. 3). The
initial degree of clinical disease severity may, therefore, more
accurately reflect the extent of primary renal injury than any
subtle differences in histology. The observation that proteinuria
was decreased at follow-up in those initially treated daily (Table
2), compared to those treated with alternate-day medication,
suggests a role for more vigorous corticosteroid therapy in the
severe clinical groups, despite the increment in glomeruloscier-
osis of this patient cohort at follow-up. It could be argued that
treatment with daily steroids may have increased the severity of
glomeruloscierosis (Fig. 3); however, this seems unlikely in
view of the generally favorable clinical outcome. Whether daily
prednisone therapy would have resulted in less proteinuria at
follow-up if employed at outset in the milder treatment catego-
ries is unknown.
The histologic indicators of active glomerular disease (gb-
merular cellularity, inflammatory activity and capillary loop
patency) were improved in the majority of patients. In contrast,
the percent gbomerulosclerosis was increased, and the intersti-
tial area was unchanged. However, since none of our patients
has demonstrated a progressive loss of renal function, no
histologic parameter can be assessed as an indicator of clinical
prognosis. In light of these histologic findings, ongoing inflam-
matory injury does not appear to be a significant factor in most
patients after several years of disease. Indeed, the initial
disease activity may have been attenuated by the early use of
corticosteroids.
Neither persistent hypocomplementemia nor abnormal uri-
nalysis at follow-up correlated statistically with renal functional
or histologic outcome. However, seven of eight patients with
normal urinalyses at follow-up had a complete resolution of
glomerular inflammatory activity on follow-up biopsy. Thus, a
repeat renal biopsy may be unnecessary in the presence of a
normal or mild urinary sediment at two to three years of
follow-up when associated with normal renal function and
normal blood pressure.
Donadio and Offord have stressed the need for well designed,
appropriately controlled, randomized clinical trials to evaluate
the efficacy of therapies in MPGN and other chronic diseases
[17]. However, many published clinical trials have had signifi-
cant limitations. For example, the controlled clinical trials of
Cattran et al [7], Zimmerman et al [12] and Tiller et al [20] all
allowed other forms of therapy up to six months preceding the
study protocols despite a duration of clinically apparent renal
disease of one [7] to three years [12]. Because MPGN I is a
chronic disease with progression over many years it does not
seem appropriate to include patients who may have been
treated with any of a variety of medications [1—16] prior to
entering a controlled clinical trial. Furthermore, the alternate-
day prednisone therapy described by McEnery et al [1], West
[22] and others included patients who were treated with various
immunosuppressives, while Lagrue's description of nonsteroi-
dal antiinflammatory therapy in 53 patients with MPGN states
that 14 (26%) were pre-treated with immunosuppressive medi-
cations [13]. In the present report all patients were treated with
corticosteroids and antihypertensive medication, with the level
of steroid therapy adjusted according to the patients' initial
degree of renal functional impairment. In view of the chronicity
of MPGN, future controlled clinical trials should exclude pa-
tients who have been treated with any medication that may
confound data analysis.
In summary, 19 children with biopsy proven MPGN I and
6.9 0.8 years of clinically apparent renal disease have
maintained normal renal function following a limited course of
prednisone. Hypertension was readily managed, and did not
preclude ongoing therapy. The data suggest that prednisone,
administered early in the disease process, may attenuate pro-
gressive inflammatory injury in children with MPGN type I. It
is important to note, however, that the control of associated
hypertension, particularly with ACEIs, may contribute to the
preservation of renal function by improving glomerular hemo-
dynamics [1, 6, 22, 24]. These and other [1, 14—16, 22, 23]
preliminary data emphasize the need for a well designed pro-
spective randomized placebo controlled clinical trial to confirm
whether early steroid therapy is, indeed, useful in MPGN type
I. A multicenter collaborative endeavor will likely be necessary
to answer this question definitively.
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Appendix. Abbrevgations
MPGN - Membranoproliferative glomerulonephntis
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- Angiotensin converting enzyme inhibitor
- End-stage renal disease
- Hematoxylin-eosin
- Electron microscopy
- Creatinine clearance
- Per os
- Intravenous
- International Study of Kidney Disease in Children
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